Drugs / GSK1247446A
last change May 2008 re-read 2 minutes ago

GSK1247446A

Vaccine

Developed for
influenza
Investigated by
GlaxoSmithKline

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00545025 Oct → Dec 2007 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00540228 Oct 2007 → May 2008 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00385840 Oct 2006 → Feb 2007 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00374842 Oct → Nov 2006 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00363077 Oct → Nov 2006 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00321373 May → Jul 2006 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00321763 Apr → Jul 2006 influenza GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as GSK1247446A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00540228
6

NCT00321763

NCT00321373

NCT00545025

NCT00385840

NCT00374842

NCT00363077

Modality Vaccine “received 1 dose of GSK1247446A vaccine adjuvanted with AS03.” NCT00321373
Route Intramuscular “The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.” NCT00321373